Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.57 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646223 | 1.00 | OPRM1 (0.59) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL20170700 | 1.00 | OPRM1 (0.59) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12960900 | 1.00 | OPRM1 (0.59) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL22058863 | 0.90 | OPRM1 (0.58) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18457576 | 0.90 | OPRM1 (0.58) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18473484 | 0.90 | OPRM1 (0.58) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18473572 | 0.90 | OPRM1 (0.58) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL23132592 | 0.89 | OPRM1 (0.57) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL21098632 | 0.89 | OPRM1 (0.57) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12929728 | 0.89 | OPRM1 (0.54) | OPRM1OPRD1OPRK1SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT ENTERPRISES LLC | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | OPRM1 5/4885OPRD1 13/4885OPRK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.